Invivyd (NASDAQ:IVVD) Surges 7.21% on FDA Fast-Track Alignment and SPEAR Study Endorsement

Invivyd (NASDAQ:IVVD) surged 7.21% in pre-market trading on December 17, 2025, signaling renewed investor confidence in its therapeutic pipeline following recent developments.

The stock's upward momentum aligns with progress in its VYD2311 antibody program, which has secured alignment with the FDA for a fast-track approval pathway. The SPEAR Study Group’s endorsement of a Long COVID study design featuring VYD2311 further reinforced its potential in post-viral care.

Recent in vitro data also highlighted the antibody’s neutralizing activity against dominant SARS-CoV-2 variants, bolstering its clinical relevance.

Investor sentiment was further supported by Invivyd’s $57.5 million public offering, which provided capital liquidity and underscored institutional backing. Despite insider selling activity and analyst price target cuts, the company’s participation in investor conferences and positive guidance from HC Wainwright analysts maintained market optimism. The stock’s performance reflects a strategic focus on monoclonal antibody development amid evolving public health priorities.

With a robust R&D roadmap and a clear path to clinical trials, Invivyd is well-positioned to capitalize on growing demand for post-viral therapies. The company's focus on addressing unmet medical needs in the Long COVID space has drawn increasing interest from both institutional and retail investors. Looking ahead, the FDA’s fast-track designation and positive clinical signals could further accelerate its commercial prospects in the coming quarters.